Wealth Enhancement Advisory Services LLC Purchases 146 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Wealth Enhancement Advisory Services LLC raised its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 0.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,597 shares of the company’s stock after buying an additional 146 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in GE HealthCare Technologies were worth $2,392,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of GEHC. Mesirow Financial Investment Management Inc. increased its stake in shares of GE HealthCare Technologies by 39.6% in the third quarter. Mesirow Financial Investment Management Inc. now owns 4,084 shares of the company’s stock valued at $383,000 after buying an additional 1,159 shares in the last quarter. LMR Partners LLP acquired a new stake in GE HealthCare Technologies in the 3rd quarter valued at about $7,387,000. Principal Financial Group Inc. raised its stake in shares of GE HealthCare Technologies by 1.9% in the third quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company’s stock worth $94,780,000 after acquiring an additional 19,010 shares during the last quarter. Everence Capital Management Inc. lifted its position in shares of GE HealthCare Technologies by 118.2% during the fourth quarter. Everence Capital Management Inc. now owns 18,870 shares of the company’s stock worth $1,475,000 after purchasing an additional 10,220 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of GE HealthCare Technologies during the third quarter valued at approximately $1,396,000. Institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the sale, the chief executive officer now directly owns 24,298 shares in the company, valued at $2,101,291.04. This represents a 12.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.27% of the stock is currently owned by insiders.

GE HealthCare Technologies Stock Down 1.4 %

Shares of GE HealthCare Technologies stock opened at $84.13 on Wednesday. GE HealthCare Technologies Inc. has a 52-week low of $71.31 and a 52-week high of $94.55. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23. The business’s 50 day simple moving average is $82.13 and its 200 day simple moving average is $84.27. The firm has a market cap of $38.44 billion, a PE ratio of 23.11, a P/E/G ratio of 2.90 and a beta of 1.11.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The company had revenue of $4.86 billion for the quarter, compared to analysts’ expectations of $4.87 billion. During the same quarter in the prior year, the business posted $0.99 EPS. The business’s revenue was up .9% compared to the same quarter last year. On average, analysts predict that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be paid a dividend of $0.035 per share. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.17%. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.85%.

Analyst Ratings Changes

Several equities research analysts have recently commented on GEHC shares. Evercore ISI lifted their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus lifted their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their target price for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. UBS Group cut shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $84.00 to $74.00 in a research report on Thursday, September 26th. Finally, BTIG Research upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $96.00.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.